DAX+2,14 % EUR/USD-0,03 % Gold-0,09 % Öl (Brent)+2,04 %

AEterna Zentaris AEZS 1000% Chance !? (Seite 797)


WKN: A1439Z | Symbol: AEZS
2,582
18.06.19
Stuttgart
-2,27 %
-0,060 EUR

Begriffe und/oder Benutzer

 

THIS AMENDED AND RESTATED SHAREHOLDER RIGHTS PLAN AGREEMENT is made as of the [8th] day of [May], 2019 (the “Agreement”).
BETWEEN:
AETERNA ZENTARIS INC., a Canadian corporation, having its registered office at [5300 Commerce Court West, 199 Bay Street, Toronto, Ontario, M5L 1B9]
(the “Corporation”)
AND:
COMPUTERSHARE TRUST COMPANY OF CANADA, 1500 Robert-Bourassa Blvd., Suite 700, Montreal, Quebec, H3A 3S8
(the “Rights Agent”)
WHEREAS:

A.

The Board of Directors of the Corporation, in the exercise of its fiduciary duties to the Corporation, has determined that it is advisable to implement a shareholder rights plan to ensure, to the extent possible, that all shareholders of the Corporation are treated fairly in connection with any take-over offer or other acquisition of control of the Corporation;

B.

The Board of Directors of the Corporation approved a shareholder rights plan of the Corporation on March 29, 2016, which was approved, ratified and confirmed by the shareholders at the annual and special meeting of shareholders of the Corporation on May 10, 2016 (the “Original Agreement”).

C.

On March 26, 2019, the Board of Directors approved certain amendments to update and restate the Original Agreement in its entirety to be on the terms and conditions and in the form of this agreement to take effect immediately upon receipt of approval of the shareholders at the annual and special meeting of shareholders which was held on [May 8], 2019;

D.

The Board of Directors had previously:

(a)

authorized and declared a distribution of one right (a “Right”) in respect of each Share outstanding at the Record Time;

(b)

authorized the issuance of one Right in respect of each Share issued after the Record Time and prior to the earlier of the Separation Time and the Expiration Time; and

(c)

authorized the issuance of Rights Certificates to holders of Rights pursuant to the terms and subject to the conditions set forth herein.

https://www.sec.gov/Archives/edgar/data/1113423/000162828019…

Nicht mehr so viel Zeit,das Bäumchen zu schütteln.

Ich sehs so,die augenblickliche kapitalisierung entspricht in etwa dem Wert des Verlustvortrages von 300 Millionen,wo ist da das produkt...:D

Aber von mir aus kanns noch gern etwas runtergehen.
sieht ja danach ganz nach einer wertvollen Übenahme aus....

Zoptarelin ist auch noch nicht ganz abgeschrieben ...

obgyn.onlinelibrary.wiley.com/doi/pdf/10.1111/jog.13980
Gropius hat ja auch schon öfters darauf hingewiesen, dass Zoptalerin noch längst nicht abgeschrieben ist...
Zop in der vorliegenden Form ist sicherlich beerdigt,aber natürlich nicht die seiner Entwicklung zugrunde liegenden Überlegungen.
Im Reagenzglas zeigte es ja an Zellkulturen,die LNHR-Rezeptoren auswiesen,ganz überragende Ergebnisse auch und gerade im Vergleich zu Doxi pur.
Neulich las ich dann eine Unistudie(leider hab ich die Fundstelle nicht mehr parat) ,die wohl zu dem Schluß kam,das das Versagen in der P3 in erster Linie darauf zurück zuführen sei,das das Bindungsmolekül zwischen LNHR-Antagonisten und dem Doxi im Realeinsatz wohl nicht stabil genug sei und daher eine große Menge des Zop sich vor Andocken an die Tumorzelle schon zerlege und,na klar,dieser Teil des Wirkstoffs sich wie normales Doxi verhalte mit all seinen Nebenwirkungen.
Man empfiehlt also,neue Bindungsmoleküle ins Auge zu fassen.
Mithin bestände hier durchaus die Möglichkeit,ein eventuell starkes secondline Präparat zu entwickeln,ob es je noch dazu kommt,vermag ich nicht zu beurteilen.
letztes offenes gap bei $ 3,69 heute geschlossen, es scheinz sich ein W-Formation zu bilden....
1 Antwort?Die Baumansicht ist in diesem Thread nicht möglich.
Antwort auf Beitrag Nr.: 60.465.809 von Banff am 01.05.19 19:24:17Welche Ergebnisse auch immer Aeterna bezüglich der Arbeit ihres Komitees bekannt geben wird,dein W wird garantiert ausradiert werden...
Die Passagen Macrilen betreffend,sind durchaus interessant,wie ich finde.

https://blueequity.io/r/31889

...

"Operator

Our next question comes from the line of Esther Hong of Janney.

Esther Hong

So first, given the agreement with Novo included about three years of using Strongbridge's sales force and reimbursement team to promote Macrilen, can we still expect a commercial infrastructure to be in place for Recorlev if U.S. launch occurs after 2021? And then, second, how is the launch of Macrilen proceeding? How are endocrinologists viewing Macrilen? Thanks.

Matthew Pauls

So first of all, thanks for the question, Esther. Just with regard to timing, actually the way this is shaping up is, it's shaping up really nicely with regard to kind of continuity and fluidity with regard to our 23-person rare endocrine field-based commercial team. Filing in the third quarter of 2020 has us potentially launching in 2021. And the timing fits very, very nicely. So we actually kind of get the maximum benefit on a number of fronts from that perspective. I hope that makes sense. And then the second part of the question was related to Macrilen. It's not our asset anymore, so we're really not commenting on it. Our 23-person rare endocrine field force is out every day in partnership with Novo and they are working away. And that's really the only comment that we can make given the fact that we no longer own the asset.

Esther Hong

And are plans still that Novo will retain 16 members of the sales force for Macrilen?

Matthew Pauls

No. So the structure of the deal is for 2019, 2020 and 2021. Our 23 employees, so these are Strongbridge employees, are working with Novo on a daily basis on Macrilen in the rare endocrine space, but they are our employees. And at the end of that three year deal, they remain our employees. So there's no retainment component, there's no crossover of our employees over to Novo, et cetera. Does that make sense, Esther?

Operator

I'm showing no further questions at this time and I'd now like to turn the call over to Strongbridge Biopharma's CEO, Matthew Pauls for closing remarks. Mr. Pauls?

Matthew Pauls

Thank you. In summary, we are very encouraged by the discussions we've had with the FDA to-date and are focused on advancing the Recorlev clinical development program and regulatory submission as quickly as possible. The data we are generating from this Phase 3 program are providing important insights into the understanding of Cushing's syndrome and the use of Recorlev. We look forward to working with healthcare professionals and patients to raise awareness of Cushing's syndrome and to providing a potential new treatment option for this difficult devastating rare disease.

Thank you for joining today's call and for your continued support.

Operator

Ladies and gentlemen, thank you for participating in today's conference. This does conclude the call. You may now disconnect. Everyone, have a wonderful day."

Offensichtlich zahlt Novo die 23 Strongbridge Vertriebsmitarbeiter bis 2021 und die sind auf Tagesbasis an Macrilen dran...
Ich denk mal eher,das war ein Goodie des macrilen deals an Strongbridge und Novo selber dürfte kaum annehmen,das die was nennenswertes auf die Reihe kriegen.

Dazu
...

"Annabel Samimy

And then in that vein, though, do you have any sense as to what's going on with Macrilen, whether Novo Nordisk has prioritized or de-prioritized this program? I think that royalty is down quite a bit.

Brian Davis

No, I think, obviously the transaction closed in December as you may recall just really right before the beginning of the quarter and we looked at the first quarter as being one of transition. So the royalty, I'll say, it wasn't unexpected from our standpoint. It was somewhat nominal. More importantly, we have our 23-person field force that is being funded. Strategically that's of significant value to us as we hope to bring Recorlev along in the relative near term and have a field force already out there. But that $7 million to $8 million per year is a very significant revenue stream for us over the three year period...."

Novo wird schon Gas geben,aber erst wen sie mit Aeterna durch sind,meine Meinung.
2 Antworten?Die Baumansicht ist in diesem Thread nicht möglich.
Antwort auf Beitrag Nr.: 60.467.117 von Skuld am 01.05.19 23:20:03300 000$/Jahr für jeden dieser Verkaufstruppe sind aber schon ein sehr großzügiges "Goodie".
Für den Betrag dürfte Novo schon Leistung fordern.

Was mir nicht klar ist: Aeterna hat doch Anspruch auf 15% Royalties von Strongbridge. In den Zahlen von Strongbridge kann ich nicht sehen, dass Royalties an Aeterna geflossen sind. Hat eventuell Novo diese Verpflichtung mit übernommen?
Nebenbei: Sehr solvent scheint mir Strongbridge auch nicht.
1 Antwort?Die Baumansicht ist in diesem Thread nicht möglich.
Antwort auf Beitrag Nr.: 60.470.318 von tupper am 02.05.19 11:59:13Ja, so wie wir das in den Filings entdecken konnten, sollte Novo direkt an Aeterna die Royalties zahlen....
 Durchsuchen


Beitrag zu dieser Diskussion schreiben